Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5409178 | 0.86 | TSHR (0.50) | KCNN4TSHRALDH1A1CYP1A2TAAR1 | |
| SCHEMBL735085 | 0.78 | CA4 (0.54) | ALDH1A1MAPK1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3879465 | 0.78 | CA4 (0.54) | ALDH1A1MAPK1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL10663447 | 0.76 | MAPK1 (0.46) | KCNN4TSHRALDH1A1MAPK1CYP1A2 | |
| SCHEMBL5409173 | 0.74 | CYP3A4 (0.39) | KCNN4TSHRALDH1A1CYP1A2TAAR1 | |
| SCHEMBL5199180 | 0.73 | TSHR (0.58) | KCNN4TSHRALDH1A1MAPK1CYP1A2 | |
| SCHEMBL10657920 | 0.73 | CYP1A2 (0.44) | KCNN4TSHRALDH1A1MAPK1CYP1A2 | |
| SCHEMBL5609995 | 0.73 | TSHR (0.58) | KCNN4TSHRALDH1A1MAPK1CYP1A2 | |
| SCHEMBL618648 | 0.73 | MAPK1 (0.50) | KCNN4TSHRALDH1A1MAPK1TAAR1 | |
| SCHEMBL230628 | 0.69 | KCNN4 (0.53) | KCNN4TSHRALDH1A1MAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024127026-A1 | MEMBRANE FILTRATION-ASSISTED SOLUTION PHASE OLIGONUCLEOTIDE SYNTHESIS | Exactmer Limited (GB) | 2024-06-20 | — | — | WO | claimed |
| US-20150119251-A1 | AGRICULTURAL PLANT-PROTECTING AGENTS CONTAINING DIPEPTIDE DERIVATIVE AS ACTIVE INGREDIENT | REPUBLIC OF KOREA (RURAL DEVELOPMENT ADMINISTRATION) (KR) | 2015-04-30 | — | — | US | claimed |
| WO-2009151744-A1 | S-NITROSOMERCAPTO COMPOUNDS AND RELATED DERIVATIVES | GALLEON PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | WO | claimed |
| US-6562844-B2 | Attaching an olefin to a solid support; oxidizing the olefin to provide an epoxide functionality; opening the epoxide with an amine to form an amino alcohol; cyclizing the amino alcohol using a phosgene equivalent | PHARMACIA & UPJOHN COMPANY | 2003-05-13 | — | — | US | claimed |
| US-6124445-A | PRO DRUGS FOR OLIGONUCLEOTIDES HAVING BIOREVERSIBLE PHOSPHATE BLOCKING GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-26 | — | — | US | claimed |
| US-5998603-A | TETRAHYDROFURANYL COMPOUNDS ARE PROVIDED THAT ARE FUNCTIONALIZED TO INCLUDE PENDANT CONJUGATE GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1999-12-07 | — | — | US | claimed |
| US-5955591-A | OLIGONUCLEOTIDES HAVING BIOREVERSIBLE PHOSPHATE BLOCKING GROUPS; USED AS PRODRUGS; ANTISENSE AGENTS | CENTER NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1999-09-21 | — | — | US | claimed |
| EP-0912592-A1 | PHOSPHOTRIESTER OLIGONUCLEOTIDES, AMIDITES AND METHOD OF PREPARATION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1999-05-06 | — | — | EP | claimed |
| WO-1997047637-A1 | PHOSPHOTRIESTER OLIGONUCLEOTIDES, AMIDITES AND METHOD OF PREPARATION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (US) | 1997-12-18 | — | — | WO | claimed |
| EP-0648220-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA, Jyoti (SE) | 1995-04-19 | — | — | EP | claimed |
| WO-1993025566-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA JYOTI (SE) | 1993-12-23 | — | — | WO | claimed |
| EP-0490450-A1 | Heterocyclic carboxylic esters, methods for their preparation and their use for the preparation of gastrointestinal medicines | YAMANOUCHI EUROPE B.V. (NL) | 1992-06-17 | — | — | EP | claimed |
| EP-0062876-B1 | 2-OXO-1-(((SUBSTITUTED SULFONYL)AMINO)CARBONYL)AZETIDINES | E.R. Squibb & Sons, Inc. (US) | 1986-09-24 | — | — | EP | claimed |
| US-4587047-A | 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines | E. R. SQUIBB & SONS, INC. (US) | 1986-05-06 | — | — | US | claimed |
| EP-0061765-B1 | BETA-LACTAMS | E.R. SQUIBB & SONS, INC. (US) | 1985-08-28 | — | — | EP | claimed |
| US-4478749-A | AMINO ACID DERTIVATIVES ANTIBIOTICS | E. R. SQUIBB & SONS, INC. (US) | 1984-10-23 | — | — | US | claimed |
| EP-0062876-A1 | 2-Oxo-1-(((substituted sulfonyl)amino)carbonyl)azetidines | E.R. Squibb & Sons, Inc. (US) | 1982-10-20 | — | — | EP | claimed |
| EP-0061765-A1 | Beta-Lactams | E.R. SQUIBB & SONS, INC. (US) | 1982-10-06 | — | — | EP | claimed |
| US-4346187-A | AND ORGANIC BROMINE COMPOUND | BORG-WARNER CHEMICALS, INC. (US) | 1982-08-24 | — | — | US | claimed |
| US-4257947-A | INTERMEDIATES FOR ANTIBACTERIAL CEPHALOSPORINS | SMITHKLINE CORPORATION (US) | 1981-03-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119251-A1 | AGRICULTURAL PLANT-PROTECTING AGENTS CONTAINING DIPEPTIDE DERIVATIVE AS ACTIVE INGREDIENT | PEPD, DNPEP, DPP7 | KCNN4 4116/4885TSHR 3540/4885ALDH1A1 4580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.